Cellular localization and functional significance of CYP3A4 in the human epileptic brain

Purpose:  Compelling evidence supports the presence of P450 enzymes (CYPs) in the central nervous system (CNS). However, little information is available on the localization and function of CYPs in the drug‐resistant epileptic brain. We have evaluated the pattern of expression of the specific enzyme CYP3A4 and studied its co‐localization with MDR1. We also determined whether an association exists between CYP3A4 expression and cell survival.

[1]  B. Volk,et al.  Expression and function of cytochrome p450 in brain drug metabolism. , 2007, Current drug metabolism.

[2]  W. Löscher,et al.  The clinical impact of pharmacogenetics on the treatment of epilepsy , 2009, Epilepsia.

[3]  A. Vezzani,et al.  Determinants of drug brain uptake in a rat model of seizure-associated malformations of cortical development , 2006, Neurobiology of Disease.

[4]  D. Kipnis,et al.  Pregnane X receptor (PXR) activation: A mechanism for neuroprotection in a mouse model of Niemann–Pick C disease , 2006, Proceedings of the National Academy of Sciences.

[5]  J. González-Martínez,et al.  The NMDA receptor NR2B subunit contributes to epileptogenesis in human cortical dysplasia , 2005, Brain Research.

[6]  C. Curti,et al.  Aromatic antiepileptic drugs and mitochondrial toxicity: effects on mitochondria isolated from rat liver. , 2008, Toxicology in vitro : an international journal published in association with BIBRA.

[7]  G. Siest,et al.  Drug metabolizing enzymes in the brain and cerebral microvessels , 1991, Brain Research Reviews.

[8]  G. Gervasini,et al.  Potential Role of Cerebral Cytochrome P450 in Clinical Pharmacokinetics , 2004, Clinical pharmacokinetics.

[9]  G. Zaccara,et al.  Adverse motor effects induced by antiepileptic drugs. , 2004, Epileptic disorders : international epilepsy journal with videotape.

[10]  J. Spence,et al.  Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition , 2000, Clinical pharmacokinetics.

[11]  Wolfgang Löscher,et al.  Drug resistance in brain diseases and the role of drug efflux transporters , 2005, Nature Reviews Neuroscience.

[12]  Z. Dvořák,et al.  Valproic Acid Induces CYP3A4 and MDR1 Gene Expression by Activation of Constitutive Androstane Receptor and Pregnane X Receptor Pathways , 2007, Drug Metabolism and Disposition.

[13]  J. González-Martínez,et al.  Transporters in Drug‐Refractory Epilepsy: Clinical Significance , 2010, Clinical pharmacology and therapeutics.

[14]  W. Löscher,et al.  P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood–brain barrier: evidence from microdialysis experiments in rats , 2002, Neuroscience Letters.

[15]  D. Nie,et al.  Human pregnane X receptor and resistance to chemotherapy in prostate cancer. , 2007, Cancer research.

[16]  S. Orkin,et al.  Transcription factor GATA-1 permits survival and maturation of erythroid precursors by preventing apoptosis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Olney,et al.  Antiepileptic drugs and apoptotic neurodegeneration in the developing brain , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Denise G. Teotico,et al.  Structural Basis of Human Pregnane X Receptor Activation by the Hops Constituent Colupulone , 2008, Molecular Pharmacology.

[19]  A. Vezzani,et al.  Significance of MDR1 and multiple drug resistance in refractory human epileptic brain , 2004 .

[20]  J. Leeder,et al.  CYP3A4-Mediated Carbamazepine (CBZ) Metabolism: Formation of a Covalent CBZ-CYP3A4 Adduct and Alteration of the Enzyme Kinetic Profile , 2008, Drug Metabolism and Disposition.

[21]  Xiaochao Ma,et al.  The pregnane X receptor: from bench to bedside. , 2008, Expert opinion on drug metabolism & toxicology.

[22]  Guo-Dong Zhou,et al.  Pregnane X receptor protects HepG2 cells from BaP-induced DNA damage. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[23]  A. Koryllou,et al.  Cell death induced by N-methyl-N-nitrosourea, a model SN1 methylating agent, in two lung cancer cell lines of human origin , 2009, Apoptosis.

[24]  G. Fricker,et al.  Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. , 2004, Molecular pharmacology.

[25]  Wei Yang Lu,et al.  Pathways of Carbamazepine Bioactivation in Vitro. III. The Role of Human Cytochrome P450 Enzymes in the Formation of 2,3-Dihydroxycarbamazepine , 2008, Drug Metabolism and Disposition.

[26]  S. Namura,et al.  Relationship between expression of multiple drug resistance proteins and p53 tumor suppressor gene proteins in human brain astrocytes , 2003, Neuroscience.

[27]  T. Giordano,et al.  Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Dieter Schmidt,et al.  Drug treatment of epilepsy: Options and limitations , 2009, Epilepsy & Behavior.

[29]  E. Aronica,et al.  Selective and persistent upregulation of mdr1b mRNA and P-glycoprotein in the parahippocampal cortex of chronic epileptic rats , 2004, Epilepsy Research.

[30]  M. Mayberg,et al.  Mechanisms of endothelial survival under shear stress. , 2002, Endothelium : journal of endothelial cell research.

[31]  G. Siest,et al.  Localization of Drug‐Metabolizing Enzyme Activities to Blood‐Brain Interfaces and Circumventricular Organs , 1994, Journal of neurochemistry.

[32]  W. Burman,et al.  Carbamazepine toxicity after starting combination antiretroviral therapy including ritonavir and efavirenz. , 2000, AIDS.

[33]  A. Palmini,et al.  Terminology and classification of the cortical dysplasias , 2004, Neurology.

[34]  J. C. Baayen,et al.  Expression and Cellular Distribution of Multidrug Resistance–related Proteins in the Hippocampus of Patients with Mesial Temporal Lobe Epilepsy , 2004, Epilepsia.

[35]  C. Daumas-Duport,et al.  ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood–brain barrier , 2008, Journal of neurochemistry.

[36]  Marie-Anne Loriot,et al.  Xenobiotic metabolizing enzymes in the central nervous system: Contribution of cytochrome P450 enzymes in normal and pathological human brain. , 2008, Biochimie.

[37]  B. Neuschwander‐Tetri,et al.  Humanized xenobiotic response in mice expressing nuclear receptor SXR , 2000, Nature.

[38]  N. Holbrook,et al.  The cellular response to oxidative stress: influences of mitogen-activated protein kinase signalling pathways on cell survival. , 1998, The Biochemical journal.

[39]  M. Mayberg,et al.  Overexpression of Multiple Drug Resistance Genes in Endothelial Cells from Patients with Refractory Epilepsy , 2001, Epilepsia.

[40]  E. Schuetz,et al.  Interaction of Cytochrome P450 3A Inhibitors with P-Glycoprotein , 2002, Journal of Pharmacology and Experimental Therapeutics.

[41]  L. Velíšek,et al.  Seizures and Antiepileptic Drugs: Does Exposure Alter Normal Brain Development in Animal Models? , 2009 .

[42]  Acute hypoxia and osteoclast activity: a balance between enhanced resorption and increased apoptosis , 2009, The Journal of pathology.

[43]  W. Löscher,et al.  Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats , 2004, Epilepsy Research.

[44]  E. Oby,et al.  The Blood–Brain Barrier and Epilepsy , 2006, Epilepsia.

[45]  Jorge Gonzalez-Martinez,et al.  Management of the patient with medically refractory epilepsy , 2009, Expert review of neurotherapeutics.

[46]  Luca Cucullo,et al.  Pattern of P450 expression at the human blood–brain barrier: Roles of epileptic condition and laminar flow , 2010, Epilepsia.

[47]  R. Levy.  Cytochrome P450 Isozymes and Antiepileptic Drug Interactions , 1995, Epilepsia.

[48]  J. Cigudosa,et al.  Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas. , 2007, Blood.

[49]  A. Mitra,et al.  MDR- and CYP3A4-Mediated Drug–Drug Interactions , 2006, Journal of Neuroimmune Pharmacology.

[50]  E. Ban,et al.  Analysis of carbamazepine and its active metabolite, carbamazepine-10,11-epoxide, in human plasma using high-performance liquid chromatography , 2006, Analytical and bioanalytical chemistry.

[51]  W. Löscher,et al.  Comparison of Brain Extracellular Fluid, Brain Tissue, Cerebrospinal Fluid, and Serum Concentrations of Antiepileptic Drugs Measured Intraoperatively in Patients with Intractable Epilepsy , 2006, Epilepsia.